American Journal of Cancer Research and Reviews

Hepatitis C Virus as risk factor for development of hepatocellular carcinoma in Egypt: I- HCV promotes HCC progression by increasing cancer stem marker (CD133 and CD44) expression

Research Article of American Journal of Cancer Research and Reviews Hepatitis C Virus as risk factor for development of hepatocellular carcinoma in Egypt: I- HCV promotes HCC progression by increasing cancer stem marker (CD133 and CD44) expression Laila H. El-Sayed 1, Manal A. Nabil 1,  Salwa Nayer. M. A 2, Saeid A. Oda 3 , Abdel Rahman M. A 4and Hossam M. Ghoneim 1 1Departement of Immunology & Allergy-Medical Research Institute, Alexandria University 2Departement of Cancer Management & Research- Medical Research Institute, Alexandria University 3Departement of Internal Medicine-Medical Research Institute, Alexandria University 4Departementof Clinical Pathology- Alexandria Military Academy Hospital Hepatitis C virus (HCV) represents a major public health problem, affecting 3% of the world’s population. In majority of infected patients, HCV can effectively evade innate immunity resulting in chronic hepatitis, which can progress to cirrhosis and hepatocellular carcinoma (HCC). Similar to most solid tumors, HCCs are believed to contain poorly differentiated cancer stem cell-like cells (CSCs) that initiate tumorigenesis and confer resistance to chemotherapy. The present work attempted to study the mRNA expression of cancer stem cell markers (CD133 and CD44) in patients with chronic hepatitis C virus (reflecting the role of HCV) and their correlation with progression toward cirrhosis and HCC. Peripheral blood mononuclear cell (PBMC) prepared from chronic HCV patients (either with or without complications) were probed for mRNA expression of CD133 and CD44 by RT-PCR and compared to that of non-HCV cirrhotic patients as well as healthy control subjects. Our results showed that mRNA expression of CD133 was significantly elevated in all HCV patients either with or without complications but not in those with non-HCV cirrhosis, with maximal expression in patients without complications (HCV patients only). On the other hand, maximal CD44 mRNA expression was recorded in HCC patients. Taken together, these results suggests that, chronic HCV ...

Dr. Elsayed Ibrahim Elagamy
Professor of Immunology, Department of Applied Medical Sciences, College of Community (Unaizah), Qassim University, Kingdom of Saudi Arabia.

Dr. Indrasena R Kummetha
University of California San Diego (UCSD), Department of Pediatrics, 9500 Gilman Drive, MC 0762, BRF-11, Room NO:2220, San Diego, California, 92093, USA

Dr. Zhiqiang Hou
Senior Research Associate, Center for Alzheimer’s and Neurodegenerative Diseases, UT Southwestern Medical Center, Dallas, TX 75390

Dr. Nisar Haider Zaidi
MBBS, MS, MRCS (Glasgow), FICS, FACS. Department of surgery, King Abdulaziz University Hospital , POBox-80215 Jeddah 21589 , Saudi Arabia

Dr. Shahin Gavanji
Chairman of “WAMS National Council of Iran at World Academy of Medical Sciences (WAMS), Chairman WAMS Oncology Research Group of Iran, Young Researchers and Elite Club, Khorasgan Branch, Islamic Azad University, Khorasgan, Isfahan, Iran, Department of Biotechnology, Faculty of Advanced Sciences and Technologies, University of Isfahan, Isfahan, Iran.

Dr. Kabita Mishra
D.D.P.R.-Central Research Institute for Homoeopathy , (Ministry of A.Y.U.S.H., Government of India)

Dr. Prakash Prajapat
Assistant Professor, Department of Chemistry, Mehsana Urban Institute of Sciences, Ganpat University

Dr. Naoshad Muhammad
Department of Radiation Oncology, School of Medicine, Washington University in Saint Louis

Manuscript Title: The title should be a brief phrase.

Author Information: List full names and affiliation of all authors, including Emails and phone numbers of corresponding author.

Abstract: The abstract should be less than 500 words. Following abstract, a list of keywords and abbreviations should be added. The keywords should be no more than 10. Abbreviation are only used for non standard and long terms.

Introduction: The introduction should included a clear statement of current problems.

Materials and Methods: This section should be clearly described.

Results and discussion: Authors may put results and discussion into a single section or show them separately.

Acknowledgement: This section includes a brief acknowledgment of people, grant details, funds

References: References should be listed in a numbered citation order at the end of the manuscript. DOIs and links to referenced articles should be added if available. Abstracts and talks for conferences or papers not yet accepted should not be cited. Examples Published Papers: 

1.ZAICHICK Vladimir and ZAICHICK Sofia. Trace Element Contents in Thyroid Cancer Investigated by Energy Dispersive X-Ray Fluorescent Analysis. American Journal of Cancer Research and Reviews, 2018,2:5. DOI: 10.28933/ajocrr-2017-12-2801 
2.Kénémé Bineta; Ciss Daouda; Ka Sidy; Mbaye Fatimata; Dem Ahmadou; Sembène Mbacké. UTERINE FIBROIDS IN SENEGAL: POLYMORPHISM OF MED12 GENE AND CORRELATION WITH EPIDEMIOLOGICAL FACTORS. American Journal of Cancer Research and Reviews, 2018,2:4. DOI:10.28933/ajocrr-2017-12-2601 

Tables and figures: Tables should be used at a minimum with a short descriptive title. The preferred file formats for Figures/Graphics are GIF, TIFF, JPEG or PowerPoint.

Publication fee: The authors will be contacted about the publication fee after a manuscript have been accepted.

Proofreading and Publication: A proof will be sent to the corresponding author before publication. Authors should carefully read the proof to avoid any errors and return the proof to the editorial office. Editorial office will publish the article shortly and send a notice to authors with the links of the paper.

Open Access

The American Journal of Cancer Research and Reviews is a peer reviewed open access journal publishing research manuscripts, review articles, case reports, editorials, letters to the editor in Cancer Research and Reviews (indexing details).

Peer Review

To ensure the quality of the publications, all submitted manuscripts will be peer-reviewed by invited experts in the field. The decisions of editors will be made based on the comments of the reviewers.

Rapid Publication

Time to first decision: within 2 days for initial decision without review, 18 days with review; Time to publication: Accepted articles will be published online within 2 days, and final corrected versions by authors will be accessible within 5 days.  More details....

Rapid Response Team

Please feel free to contact our rapid response team if you have any questions. Our customer representative will answer your questions soon.

American Journal of Cancer Research and Reviews